TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03954236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical ruxolitinib 1.5% cream
Description: Patients will be prescribed twice daily use of topical ruxolitinib 1.5% cream (randomized half of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days. Topical ruxolitinib will be provided as topical cream. At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical ruxolitinib 1.5% cream
Description: Patients will be prescribed twice daily use of topical ruxolitinib 1.5% cream (randomized half of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days. Topical ruxolitinib will be provided as topical cream. At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical vehicle/moisturizer cream
Description: Patients will be prescribed twice daily use of vehicle/moisturizer (for contralateral side of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days.At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical vehicle/moisturizer cream
Description: Patients will be prescribed twice daily use of vehicle/moisturizer (for contralateral side of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days.At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
Study: NCT00830362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 40 mg administered once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered once
Study: NCT01365910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linifanib
Description: Given PO
Study: NCT01587001

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl-cysteine
Description: 900mg three times daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo three times daily for 8 weeks.
Study: NCT01781143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perform Echo at home.
Description: A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
Study: NCT00834171

Intervention type: DRUG
Intervention: Loteprednol etabonate ophthalmic suspension 0.5%
Description: Apply one to two drops of Loteprednol etabonate ophthalmic suspension 0.5% into the conjunctival sac as prescribed by your physician

Intervention type: DRUG
Intervention: Loteprednol etabonate (0.5%) and tobramycin (0.3%).
Description: Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.
Study: NCT00554528

Intervention type: DEVICE
Group type: OTHER
Intervention: cervical disc prosthesis with a mobile insert named Mobi-C
Description: Stage 1: partial discectomy~stage 2: location of the medial axis~stage 3: centering pin~stage 4: installation of the caspar spacer~stage 5: total discectomy~stage 6: parallel distraction~stage 7: depth measurement~stage 8: trial implant~stage 9: assembly~stage 10: implant insertion~stage 11: anchorage optimization

Intervention type: PROCEDURE
Group type: OTHER
Intervention: arthrodesis - cervical disk surgery
Description: discectomy and arthrodesis
Study: NCT00828659

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator #1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator #2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator #3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin Dose #1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin Dose #2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin Dose #3
Study: NCT01486667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxine
Description: Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of levothyroxine. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of drug will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of medication. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
Study: NCT00672243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib + sirolimus
Description: Erlotinib \& sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of oral erlotinib and 5mg of oral sirolimus for patients not on concurrent CY3PA-inducing anti-epileptics (EIAEDS) and 400 mg of oral erlotinib and 10 mg of oral sirolimus for patients on concurrent EIAEDS.
Study: NCT03295747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peppermint oil
Description: Three doses of peppermint oil will be investigated: 180, 360, 540 mg; i.e. three arms.
Study: NCT03224156

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Resonance Imaging
Description: Patients undergo baseline characterisation including CMR, ECG, blood samples prior to ICD implantation.
Study: NCT02858713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene + Betamethasone Dipropionate
Description: Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period.
Study: NCT01734356

Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsies

Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsies

Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsies
Study: NCT03474770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIS-001ER
Description: BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
Study: NCT02858713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App
Description: App named MyPso SmarTopTM Version 1.0 (LEO Pharma) was used for 28 days by participants in the intervention arm.
Study: NCT02337660

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver biopsy
Description: One ultrasound guided liver biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver biopsy
Description: One ultrasound guided liver biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pancreatic clamp
Description: I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pancreatic clamp
Description: I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.
Study: NCT00629707

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intravenous fluid treatment
Description: infusion of intravenous fluids (0.9% saline and 0.45% saline)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intravenous fluid treatment
Description: infusion of intravenous fluids (0.9% saline and 0.45% saline)
Study: NCT03295747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peppermint oil
Description: Three doses of peppermint oil will be investigated: 180, 360, 540 mg; i.e. three arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peppermint oil
Description: Three doses of peppermint oil will be investigated: 180, 360, 540 mg; i.e. three arms.
Study: NCT01277250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation program
Description: Web-based smoking cessation program that includes a transition coach to hospitalized patients who will assist them in quitting as they are discharged from the hospital. Intervention arm participants will have access to a tailored web-based intervention that will include e-messages and activities that are tailored to their recent hospital stay.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Web-based smoking cessation program
Description: Web-based smoking cessation program that includes a transition coach to hospitalized patients who will assist them in quitting as they are discharged from the hospital. Intervention arm participants will have access to a tailored web-based intervention that will include e-messages and activities that are tailored to their recent hospital stay.
Study: NCT03344588

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: artery preserving varicocelectomy
Description: During sub-inguinal varicocelectomy, testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: artery ligation varicocelectomy
Description: During sub-inguinal varicocelectomy, all vascular channels will be ligated without identifying or sparing the internal spermatic arteries.
Study: NCT01837238

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB
Description: Following this initial round of testing,participant will be assigned to daily HMB supplementation for 6 months. You will be asked to consume a 1000mg HMB capsule 3 times per day, 7 days per week, for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo group will consume non-nutritive placebo pills daily for 6 months.
Study: NCT01331044

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plumpy Nut
Description: to RUTF will receive commercially available RUTF (Plumpy nut) in a total of 200 kcal/kg.day in a sequential manner (Plumpy nut will be offered \~ 125 kcal/kg in 1st 24 hours, \~ 150 kcal/kg in 2nd 24 hours, then\~200k cal/kg by the third day).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Khichuri and Halwa
Description: Day 1: Milk suji, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day 125kcal/kg.day~Day 2: Milk suji, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day \& khichuri 10gm/kg; 2 feed per day 150kcal/kg.day~Day 3: Milk suji 100, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day \& khichuri 10gm/kg; 2 feed per day 175kcal/kg.day~Day 4: Milk suji 100, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 3 feed per day \& khichuri 10gm/kg; 3 feed per day 200kcal/kg.day~Day 5 onward: Milk suji 100, 10ml/kg/ feed 6 hourly (4 feed per day) \& halwa 20gm/kg; 3 feed per day \& khichuri 20gm/kg; 3 feed per day 200kcal/kg.day
Study: NCT02566902

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-Piece Nebulizer
Description: Albuterol treatment administered with Hudson RCI® Micro Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath-Enhanced Nebulizer
Description: Albuterol treatment administered with NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer (Salter Labs®, Arvin, CA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: One time 5mg nebulized albuterol treatment given with one of two devices over 10 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: One time 5mg nebulized albuterol treatment given with one of two devices over 10 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-Treatment Spirometry Measurement
Description: Bedside spirometry measurements taken prior to albuterol therapy using ndd® EasyOne Plus® spirometer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Treatment Spirometry Measurement
Description: Bedside spirometry measurements taken prior to albuterol therapy using ndd® EasyOne Plus® spirometer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-Treatment Spirometry Measurement
Description: Bedside spirometry measurements taken after albuterol therapy using ndd® EasyOne Plus® spirometer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post-Treatment Spirometry Measurement
Description: Bedside spirometry measurements taken after albuterol therapy using ndd® EasyOne Plus® spirometer.
Study: NCT03879460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Hydrochloride
Description: 50 mg per os naltrexone hydrochloride
Study: NCT01723176

Intervention type: PROCEDURE
Intervention: Echocardiography
Study: NCT04426292

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serological testing
Description: Antibody testing for Sars-COV-2 antibodies in blood.
Study: NCT03967847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Oral Ketorolac
Study: NCT01498770

Intervention type: DRUG
Intervention: Asenapine
Description: Asenapine prescribed as recorded in the CPRD in the UK

Intervention type: DRUG
Intervention: Aripiprazole
Description: Aripiprazole prescribed as recorded in the CPRD in the UK

Intervention type: DRUG
Intervention: Quetiapine
Description: Quetiapine prescribed as recorded in the CPRD in the UK

Intervention type: DRUG
Intervention: Risperidone
Description: Risperidone prescribed as recorded in the CPRD in the UK

Intervention type: DRUG
Intervention: Olanzapine
Description: Olanzapine prescribed as recorded in the CPRD in the UK

Intervention type: DRUG
Intervention: Ziprasidone
Description: Ziprasidone prescribed as recorded in the CPRD in the UK

Intervention type: DRUG
Intervention: Iloperidone
Description: Iloperidone prescribed as recorded in the CPRD in the UK

Intervention type: DRUG
Intervention: Paliperidone
Description: Paliperidone prescribed as recorded in the CPRD in the UK
Study: NCT03924089

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement with probiotics
Description: Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), with probiotics.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement without probiotics
Description: Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), without probiotics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary recommendations
Description: Dietary recommendations
Study: NCT02041156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic and resistance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic combined with balance training
Study: NCT02212613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally
Study: NCT01231399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies
Study: NCT02808156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unilateral upper limbs intensive training
Description: The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bilateral upper limbs intensive training
Description: The bimanual intensive training focuses activities that required the use of both hands.
Study: NCT01136967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
Study: NCT02562339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART-3RP
Description: 8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART-3RP
Description: 8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
Study: NCT04428216

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group RIB
Description: In group RIB, RIB block will be performed. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study: NCT01498770

Intervention type: DRUG
Intervention: Lurasidone
Description: Lurasidone prescribed as recorded in the CPRD in the UK

Intervention type: DRUG
Intervention: Clozapine
Description: Clozapine prescribed as recorded in the CPRD in the UK

Intervention type: DRUG
Intervention: Amisulpride
Description: Amisulpride prescribed as recorded in the CPRD in the UK

Intervention type: DRUG
Intervention: Sertindole
Description: Sertindole prescribed as recorded in the CPRD in the UK
Study: NCT04459533

Intervention type: DEVICE
Intervention: TOF protocol
Description: To the introduction of CISATRACURIUM, Initial bolus was at 0.2mg/kg and initial continuous infusion at 0.18mg/kg/h of theoretical ideal weight.~To the introduction of ATRACURIUM, initial bolus was at 0.5mg/kg and initial continuous infusion at 0.5mg/kg/h of theoretical ideal weight.~Introduction of NMBA was associated to deep sedation (RASS - 4 or RAMSAY 6; BIS 40 to 60).~TOF was measured through the electric stimulation of peripheral nerves (facial or ulnar nerve).~The dose of NMB agents was then adapted according to the number of answers to the TOF, per 4 hours:~* If 0 response and no respiratory asynchrony: no change in flow rate~* If \>=1 or respiratory asynchrony: increase of the continuous curare flow by 20% preceded by a bolus identical to the one administered at the beginning of NMB agent, then recheck at H+1.
Study: NCT02392143

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed Education Material
Description: The printed education material described the importance of early detection and prevention, risk factors, and the importance of talking to your doctor about CRC screening. The PEM highlighted colonoscopy as being the only test that can identify and prevent CRC and described how to prepare for a colonoscopy beginning seven days prior to the test \[18\]. The PEM also described other CRC screening tests, including the FOBT, FIT, sigmoidoscopy, barium enema and virtual colonoscopy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Academic Detailing
Description: Academic detailing (AD) involved an in-person visit from a member of the research team who attempted to communicate strategies for improving CRC screening uptake in the practice's patient panel. A brief description of the RCT was followed by a semi-structured interview assessing usual practice regarding CRC screening referral and follow up. The direction of the discussion was guided by PCP responses. A variety of resources were provided. Specific directives were following up to make sure patients had made appointments with a gastroenterologist and offering home stool tests. The detailer attempted to elicit a verbal commitment to do at least one new thing to strengthen the probability that patients would be screened.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Academic Detailing+Telephone Education
Description: PCPs received AD as described in the Academic Detailing arm. In addition, participants received tailored telephone education (TTE) which focused on identifying and addressing barriers that might impede screening. Verbal commitments were elicited to speak with their PCP and make an appointment for a colonoscopy, or request a home stool test, as appropriate. Follow-up calls assessed progress towards achieving goals.